vs
Avantor, Inc.（AVTR）与Bionano Genomics, Inc.（BNGO）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Bionano Genomics, Inc.的209.2倍（$1.7B vs $8.0M）。Avantor, Inc.净利率更高（3.1% vs -99.8%，领先102.9%）。Avantor, Inc.同比增速更快（-1.4% vs -2.6%）。过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -4.8%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Bionano Genomics是一家基因组技术企业，开发并销售专有光学基因组测绘技术及相关诊断解决方案，可高精度检测基因组大型结构变异，服务全球学术研究机构、生物制药企业与临床诊断实验室，产品应用于肿瘤、罕见病研究等领域。
AVTR vs BNGO — 直观对比
营收规模更大
AVTR
是对方的209.2倍
$8.0M
营收增速更快
AVTR
高出1.2%
-2.6%
净利率更高
AVTR
高出102.9%
-99.8%
两年增速更快
AVTR
近两年复合增速
-4.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $8.0M |
| 净利润 | $52.4M | $-7.9M |
| 毛利率 | 31.5% | 42.8% |
| 营业利润率 | 7.6% | -107.4% |
| 净利率 | 3.1% | -99.8% |
| 营收同比 | -1.4% | -2.6% |
| 净利润同比 | -89.5% | 60.6% |
| 每股收益（稀释后） | $0.08 | $-0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRBNGO
| Q4 25 | $1.7B | $8.0M | ||
| Q3 25 | $1.6B | $7.4M | ||
| Q2 25 | $1.7B | $6.7M | ||
| Q1 25 | $1.6B | $6.5M | ||
| Q4 24 | $1.7B | $8.2M | ||
| Q3 24 | $1.7B | $6.1M | ||
| Q2 24 | $1.7B | $7.8M | ||
| Q1 24 | $1.7B | $8.8M |
净利润AVTRBNGO
| Q4 25 | $52.4M | $-7.9M | ||
| Q3 25 | $-711.8M | $-8.5M | ||
| Q2 25 | $64.7M | $-6.9M | ||
| Q1 25 | $64.5M | $-3.1M | ||
| Q4 24 | $500.4M | $-20.1M | ||
| Q3 24 | $57.8M | $-44.2M | ||
| Q2 24 | $92.9M | $-16.2M | ||
| Q1 24 | $60.4M | $-31.4M |
毛利率AVTRBNGO
| Q4 25 | 31.5% | 42.8% | ||
| Q3 25 | 32.4% | 45.7% | ||
| Q2 25 | 32.9% | 51.6% | ||
| Q1 25 | 33.8% | 45.5% | ||
| Q4 24 | 33.4% | 41.9% | ||
| Q3 24 | 32.9% | -139.1% | ||
| Q2 24 | 34.1% | 33.3% | ||
| Q1 24 | 34.0% | 32.2% |
营业利润率AVTRBNGO
| Q4 25 | 7.6% | -107.4% | ||
| Q3 25 | -40.0% | -115.9% | ||
| Q2 25 | 7.7% | -115.8% | ||
| Q1 25 | 9.3% | -131.1% | ||
| Q4 24 | 37.8% | -146.3% | ||
| Q3 24 | 7.3% | -722.9% | ||
| Q2 24 | 10.3% | -219.0% | ||
| Q1 24 | 8.7% | -354.9% |
净利率AVTRBNGO
| Q4 25 | 3.1% | -99.8% | ||
| Q3 25 | -43.8% | -115.4% | ||
| Q2 25 | 3.8% | -101.8% | ||
| Q1 25 | 4.1% | -48.0% | ||
| Q4 24 | 29.7% | -246.5% | ||
| Q3 24 | 3.4% | -728.6% | ||
| Q2 24 | 5.5% | -208.8% | ||
| Q1 24 | 3.6% | -358.3% |
每股收益（稀释后）AVTRBNGO
| Q4 25 | $0.08 | $-0.12 | ||
| Q3 25 | $-1.04 | $-1.59 | ||
| Q2 25 | $0.09 | $-1.99 | ||
| Q1 25 | $0.09 | $-1.15 | ||
| Q4 24 | $0.73 | $-7.05 | ||
| Q3 24 | $0.08 | $-30.92 | ||
| Q2 24 | $0.14 | $-14.41 | ||
| Q1 24 | $0.09 | $-35.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $3.0M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $44.4M |
| 总资产 | $11.8B | $73.6M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRBNGO
| Q4 25 | $365.4M | $3.0M | ||
| Q3 25 | $251.9M | $3.1M | ||
| Q2 25 | $449.4M | $3.6M | ||
| Q1 25 | $315.7M | $3.6M | ||
| Q4 24 | $261.9M | $9.2M | ||
| Q3 24 | $285.3M | $8.8M | ||
| Q2 24 | $272.6M | $10.4M | ||
| Q1 24 | $234.9M | $15.8M |
总债务AVTRBNGO
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRBNGO
| Q4 25 | $5.6B | $44.4M | ||
| Q3 25 | $5.6B | $49.8M | ||
| Q2 25 | $6.3B | $45.4M | ||
| Q1 25 | $6.1B | $48.2M | ||
| Q4 24 | $6.0B | $35.4M | ||
| Q3 24 | $5.6B | $48.9M | ||
| Q2 24 | $5.4B | $80.3M | ||
| Q1 24 | $5.3B | $82.8M |
总资产AVTRBNGO
| Q4 25 | $11.8B | $73.6M | ||
| Q3 25 | $11.7B | $79.1M | ||
| Q2 25 | $12.8B | $76.0M | ||
| Q1 25 | $12.3B | $78.4M | ||
| Q4 24 | $12.1B | $76.7M | ||
| Q3 24 | $12.8B | $87.4M | ||
| Q2 24 | $12.7B | $129.4M | ||
| Q1 24 | $12.8B | $158.0M |
负债/权益比AVTRBNGO
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-4.2M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRBNGO
| Q4 25 | $152.7M | $-4.2M | ||
| Q3 25 | $207.4M | $-5.9M | ||
| Q2 25 | $154.4M | $-3.5M | ||
| Q1 25 | $109.3M | $-2.8M | ||
| Q4 24 | $173.3M | $-6.5M | ||
| Q3 24 | $244.8M | $-13.3M | ||
| Q2 24 | $281.1M | $-21.0M | ||
| Q1 24 | $141.6M | $-28.1M |
自由现金流AVTRBNGO
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — | ||
| Q1 24 | $106.9M | — |
自由现金流率AVTRBNGO
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.4% | — |
资本支出强度AVTRBNGO
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | — |
现金转化率AVTRBNGO
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
BNGO
暂无分部数据
